Adjuvant treatment for young women with early breast cancer

Minerva Ginecologica

Volumn 59, Issue 5, 2007, Pages 513-527

  Balduzzi, A ^a,b   Cardillo, A ^a   D'Alessandro, C ^a   Colleoni, M ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE   (Italy)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, therapy; Chemotherapy, adjuvant

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; METHOTREXATE; PACLITAXEL; PLACEBO; STEROID RECEPTOR; TAMOXIFEN; TRIPTORELIN;

ADJUVANT THERAPY; AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DECISION MAKING; EARLY MENOPAUSE; GENE MUTATION; GENE OVEREXPRESSION; HORMONAL THERAPY; HORMONE RELEASE; HUMAN; INCIDENCE; MENOPAUSE; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARIECTOMY; OVARY DISEASE; OVARY FIBROSIS; OVARY FUNCTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WOMEN'S HEALTH;

AGE FACTORS; AGE OF ONSET; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INCIDENCE; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TAMOXIFEN; TAXOIDS;

EID: 36749037747     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968;168:337-56.
2. McDonald GO, Cruz EP, Cole WH. The effect of cancer inhibitor drugs on the "take" of Walker carcinosarcoma 256 in rats. Surg Forum 1956;7:486-97.
3. Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117-22.
4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294:405-10.
5. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, Smith TL et al. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 1978;41:1064-75.
6. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988;319:1681-92.
7. Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Volume 1: Worldwide evidence 1985-1990. New York, NY: University Press; 1990.
8. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15.
9. Polichemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
10. Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr 2001;30:72-9.
11. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2000;52:23-47.
12. rd ed. Baltimore, MD: Lippincott Williams & Wilkins; 2004. p. 1339-49.
13. Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am 1998;27:989-1006.
14. Morimoto T, Okazaki M, Endo T. Current status and goals of mammographic screening for breast cancer in Japan. Breast Cancer 2004;11:73-81.
15. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med 1986;315:559-63.
16. Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B et al. Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer 2002;3:65-72.
17. Surveillance, Epidemiology, and End Results (SEER) Program Public-Use CD ROM (1973-1997), National Cancer Institute, DCCPS, Cancer Surveillance Research Program, Cancer Statistics Branch, released April 2000, based on the August 1999 submission.
18. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996;74:1796-800.
19. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103.
20. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer - histopathological and prognostic considerations. Br J Cancer 1997;75:1318-23.
21. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer 1996;78:1838-43.
22. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994;16:69-77.
23. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997;33:425-8.
24. Albain KS, Green S, LeBlanc M, Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat 1992;22:273-84.
25. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J 2000;320:474-8.
26. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994;16:35-42.
27. Noyes RD, Spanos WJ Jr, Montague ED. Breast cancer in women aged 30 and under. Cancer 1982;49:1302-7.
28. Ribeiro GG, Swindell R. The prognosis of breast carcinoma in women aged less than 40 years. Clin Radiol 1981;32:231-6.
29. A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Ludwig Breast Cancer Study Group. Cancer Res 1985;45:4454-9.
30. Chemotherapy with or without oophorectomy in high risk premenopausal patients with operable breast cancer. Ludwig Breast Cancer Study Group. J Clin Oncol 1985;3:1059-67.
31. Combination adjuvant chemotherapy for node positive breast-cancer. Inadequacy of a single perioperative cycle. Ludwig Breast Cancer Study Group. N Engl J Med 1988;319:677-83.
32. Prolonged disease free-survival after one course of perioperative adjuvant chemotherapy for node - negative breast cancer. Ludwig Breast Cancer Study Group. N Engl J Med 1989;320:491-6.
33. Duration and reintroduction of adjuvant chemotherapy for node- positive premenopausal breast cancer patients. International Breast Cancer Study Group. J Clin Oncol 1996;14:1885-94.
34. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber MD, Collins J, Thurlimann B et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000;355:1869-74.
35. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialist's Collaborative Group. Lancet 1998;351:1451-67.
36. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989;320:473-8.
37. Bonadonna G, Valagussa P, Tancini G, Rossi A, Brambilla C, Zambetti M et al. Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr 1986;(1):45-9.
38. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
39. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
40. Bonadonna G. Adjuvant castration versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 1978;4:918-9.
41. Bonadonna G, Valagussa P. Adjuvant chemoendocrine therapy in breast cancer. J Clin Oncol 1986;4:451-4.
42. Goldhirsch A, Gelber RD, Davis BW. Adjuvant chemotherapy trials in breast cancer: an appraisal and lessons for patient care outside the trials. In: Forbes JF editor. Breast disease. Edinburgh, UK: Churchill Livingstone; 1986. p. 123-38.
43. Fidler IJ, Ellis LM. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8.
44. Ono I, Gunji H, Suda K, Iwatsuki K, Kaneko F. Evaluation of cytokines in donor site wound fluid. Scand J Plast Reconstr Surg Hand Surg 1994;28:269-73.
45. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995;346:1334-5.
46. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
47. Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305:1-6.
48. Fisher B, Wickerham D, Redmond C, Wolmark N, Glass A, Bowman D et al. Increased benefit from addition of adriamycin to adjuvant therapy for stage II breast cancer: results from NSABP Protocols B-11 and -12. Proc ASCO 1987;6:62.
49. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-96.
50. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-18.
51. Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:1858-69.
52. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-88.
53. Tormey DC, Gray RJ, Gilchrist K, Grage T, Carbone PP, Wolter J et al. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial. Cancer 1990;65:200-6.
54. Davidson N, O'Neill A, Vukov A, Osborne CK, Martino S, White D et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proc ASCO 1999;18:67A.
55. Fetting JH, Gray R, Fairclough D, Smith TJ, Margolin KA, Citron ML et al. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor negative breast cancer: an Intergroup study. J Clin Oncol 1998;16:2382-91.
56. Hutchins L, Green S, Ravdin P, Lew D, Martino S, Abeloff M et al. CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of Intergroup trial INT 0102 [abstract]. Proc ASCO 1998;17:1A.
57. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K et al. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. J Clin Oncol 2000;18:584-90.
58. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 1983;43:1488-92.
59. Fisher B, Gunduz N, Coile J, Rudock C, Saffer E. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001.
60. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2005;365: 1687-17.
61. Hortobagyi GN, Buzdar AU. Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs 1993;45 Suppl 2:10-9.
62. Valagussa P, Zambetti M, Biasi S, Moliterni A, Zucali R, Bonadonna G. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann Oncol 1994;5:209-16.
63. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna, Pistotti V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439-60.
64. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 1991;9: 1124-30.
65. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results From NS-ABP B-28. J Clin Oncol 2005;23:3686-96.
66. Henderson IC, Berry DA, Dimetri GD, Cirrincione CT, Goldstein LJ, Martino S et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
67. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Canc Res 2002;8:1073-9.
68. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol 1990;1:183-8.
69. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34: 632-40.
70. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group: Lancet 1996;348:1189-96.
71. Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 1997;43:183-90.
72. Wiebe VJ, Osborne CK, Fuqua SA, De Gregorio MW. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993;14:173-88.
73. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M et al. HER2 amplification impedes the antiproliferative effects of hormonal therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8.
74. Davidson NE. Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001;30: 67-7.
75. Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004;112:357-64.
76. Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001;93: 112-20.
77. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Nolvadex Adjuvant Trial Organization. Br J Cancer 1988;57: 608-11.
78. Fisher B, Costantino J, Redmond C, Fisher ER, Wickerham DL, Cronin WM et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
79. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90.
80. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001;93:456-62.
81. Boccardo F, Amoroso D, Rubagotti A, Sismondi P, De Sanctis C, Cappellini M et al. Endocrine therapy of breast cancer: The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA). Ann N Y Acad Sci 1993;698:318-29.
82. Kaufmann M, Jonat W, Able U, Hilfrich J, Caffier H, Kreienberg R et al. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer. J Clin Oncol 1993;11:454-60.
83. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84.
84. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95:353-61.
85. Love RR, Due NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL et al. HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21:453-7.
86. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90:590-4.
87. Gelber RD, Castiglione-Gertsch M, Coates AS. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: the open questions. Breast 2003;12 Suppl 1:S43.
88. Francis P, Fleming G, Nasi ML. Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PgR+) breast cancer: The SOFT, TEXT, and PERCHE trials. Breast 2003;12 Suppl 1:S44.
89. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 2001;10:130-8.
90. Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R et al. Combined tamoxifen and luteinizing hormone releasing hormone (LHRH. agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
91. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20:4621-7.
92. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P et al. Cyclophosphamide, methotrexate and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000;18: 2718-27.
93. Roche HH, Kerbrat P, Bonneterre J. Complete hormonal blockade versus chemotherapy in premenopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 1-3 node-positive (N+) tumor: Results of the FASG 06 trial. Proc Am Soc Clin Oncol 2000;19:72A.
94. Davidson NE, O'Neill A, Vukov AM, Osborne CK, Martino S, White DR et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol 2005;23:5869-72.